增加的VIIa因子-抗素复合体与心脏动患者中风或心血管死亡有关
Elżbieta Szczygieł-Pilut1, Michał Błaż1, Elżbieta Pociask2
1Department of Neurology, St John Paul II Hospital, Kraków, Poland.
European journal of clinical investigation
|June 19, 2025
概括
高水平的VIIa-抗素因子 (FVIIa-AT) 复合体,组织因子 (TF) 暴露的标志物,与心房动 (AF) 患者的血栓栓塞事件和心血管死亡风险增加有关.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 血栓形成的研究研究
背景情况:
- 前庭动 (AF) 的特征是前血栓状况.
- 组织因子 (TF) 暴露有助于这种前血栓状况.
- 因子VIIa-抗素 (FVIIa-AT) 复合体作为TF活性的标记物.
研究的目的:
- 调查FVIIa-AT复合体与非膜AF患者的血栓栓塞事件之间的关联.
- 确定FVIIa-AT复合体是否是AF中心血管不良结果的独立预测因素.
主要方法:
- 研究了一组224名非膜性AF患者,其中71%的人服用直接口服抗凝剂.
- 测量包括FVIIa-AT复合体,内源性血栓潜力 (ETP),·维勒布兰德因子 (VWF) 和8-异质.
- 对患者进行了平均53个月的随访,以结合缺血性中风,全身血栓栓塞或心血管死亡的综合终点.
主要成果:
- 在患有永久性AF,血管疾病,先前中风和吸烟史的患者中观察到更高的FVIIa-AT复合体.
- FVIIa-AT复合体与NT-proBNP和ETP正相关.
- 经历复合终点的患者具有显著更高的基线FVIIa-AT复合体.
- 在顶部四分位数中增加的FVIIa-AT复合体与复合终点的风险增加12倍相关 (HR 12.0).
- FVIIa-AT复合体和VWF独立地与复合终点相关.
结论:
- 血FVIIa-AT复合物的升高与AF患者血栓栓塞事件或心血管死亡风险增加独立相关.
- 这些发现表明,残留的TF介导凝血有助于AF中的血栓形成风险.
- 结果表明,在某些AF患者群体中,可能需要更强大的抗凝策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis I: Introduction
47
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
47
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
42
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
42
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K


